Funizol

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Funizol

What is Funizol?

Funizol is an antifungal medication primarily used to treat a variety of fungal infections. It belongs to a class of drugs known as azole antifungals. These medications work by interfering with the synthesis of ergosterol, a critical component of fungal cell membranes. By disrupting the membrane's integrity, the medication inhibits the growth and reproduction of the fungi responsible for the infection.

Mechanism of Action

The active therapeutic process involves the inhibition of the enzyme cytochrome P450-dependent 14α-demethylase. In fungi, this enzyme is essential for converting lanosterol into ergosterol. When this conversion is blocked, the fungal cell membrane becomes permeable and unstable, eventually leading to the cessation of fungal growth or the death of the fungal cells.

Therapeutic Applications

Funizol is utilized in the management of both systemic and localized fungal conditions. Common applications include:

  • Dermatological Infections: Treatment of fungal skin infections such as ringworm, athlete's foot, and pityriasis versicolor.
  • Mucosal Infections: Management of oral thrush and esophageal candidiasis.
  • Systemic Mycoses: Treatment of deeper, more internal infections like aspergillosis, cryptococcosis, or histoplasmosis, which can affect the lungs and other organs.
  • Onychomycosis: Addressing fungal infections that affect the fingernails or toenails.

Due to its broad-spectrum activity, the medication is effective against a wide range of pathogens, including various species of Candida, Aspergillus, and dermatophytes.

Regulatory References

  1. NCBI Bookshelf Antifungal Agents

What side effects are possible with Funizol?

Possible Side Effects and Safety Information

The safety profile of Funizol (Fluconazole) is documented in regulatory labeling by classifying potential adverse reactions according to the frequency of their occurrence in clinical use and by the body system affected.

Frequency-Classified Adverse Reactions

Adverse events are formally classified in official documents, with common reactions primarily involving the Gastrointestinal and Nervous Systems.

Classification Examples of Reactions
Very Common Headache, increased blood alkaline phosphatase (lab value)
Common Nausea, vomiting, abdominal pain, diarrhea, rash, elevated liver enzymes (ALT, AST)
Uncommon Anemia, dizziness, insomnia, taste perversion, pruritus, hypokalemia
Rare Agranulocytosis, anaphylaxis, severe skin reactions, hepatic failure, Torsade de Pointes

Clinically Significant Safety Considerations

The regulatory profile highlights the potential for Serious Adverse Reactions (SCARs), including severe Hepatic Toxicity (which can progress to hepatic failure) and life-threatening Severe Cutaneous Adverse Reactions such as Stevens-Johnson Syndrome. Rare but critical events affecting the Cardiac System include QT prolongation and the ventricular arrhythmia Torsade de Pointes.

For specific patient populations, safety notes address use in Renal Impairment (where clearance is reduced) and potential risks associated with high-dose, chronic use during the first trimester of pregnancy (congenital defects). Furthermore, the official labeling mandates monitoring for the development of more serious hepatic injury if liver function tests become abnormal. The potential for reactions such as dizziness or seizures requires consideration regarding activities like operating machinery.

Overdose and Emergency Response

Officially documented overdose of Funizol (Fluconazole) is associated with severe neurobehavioral and cardiovascular manifestations, as described in regulatory sources.

Documented Manifestations

Overdosage has been formally documented to present with central nervous system effects, including hallucinations (seeing or hearing things that do not exist) and states of paranoia (extreme suspicion or fear). There is also a potential risk of seizures associated with severe overexposure.

Life-Threatening Risks

The primary serious risk of high plasma concentrations is the potential for QT interval prolongation and the subsequent development of Torsade de pointes, a life-threatening, abnormal heart rhythm. Due to the cardiovascular risk, ECG monitoring is implicitly required during the management of overdosage.

Required Emergency Action

Regulatory guidance mandates that immediate medical attention must be sought for any suspected overdose. Emergency services should be contacted for critical symptoms, such as the onset of seizures, collapse, difficulty breathing, or inability to be awakened. In such situations, contact with a poison control center is also advised.

Official Supportive Management

No specific antidote is known for Funizol overdosage. Management is defined by official labeling as symptomatic and supportive treatment. Where clinically necessary, measures such as gastric lavage may be utilized. Furthermore, hemodialysis has been documented as a procedure that can effectively reduce the drug's concentration in the bloodstream.

Therapeutic Uses of Funizol

What Funizol Treats: Main Uses and Benefits

Funizol (Fluconazole) is commonly used across domains where additional symptomatic support is needed to manage fungal infections.

Supporting Systemic Stability and Prevention

The medication is considered relevant in contexts involving heightened systemic burden, primarily when managing serious fungal infections of the blood, lungs, or brain (such as cryptococcal meningitis). It is applied in clinical settings that involve acute or unstable symptom patterns. Furthermore, it plays a role in managing anticipated symptomatic episodes by providing prophylactic support, which is considered relevant in preventing infections in high-risk patients, and helps maintain a sense of stability in situations where patients may experience heightened susceptibility to infection.

Managing Localized Discomfort and Functional Strain

Funizol is also relevant for managing symptom clusters that may become intense or disruptive in specific areas, such as oral thrush, vaginal yeast infections, and certain skin or nail fungal conditions. For these conditions, it is applied in addressing symptoms related to inflammatory or irritative states—like pain, burning, and itching—which are symptoms that interfere with daily functioning. Supportive relief in these areas supports general well-being during symptomatic periods.

Quick Fact: Use in managing Irritative Symptoms

Funizol may assist with managing symptoms such as pain, itching, and burning associated with superficial fungal infections, and supports general well-being during symptomatic periods.

Regulatory References

  1. NIH MedlinePlus overview of Fluconazole uses

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Funizol

The official regulatory documents define clear population eligibility for Funizol (Fluconazole).

Contraindicated and Restricted Use

Use of Funizol is contraindicated in patients with a known hypersensitivity to the medicine or other azole antifungals. It is also prohibited for patients taking specific medications that are known to prolong the QT interval and are metabolized by the CYP3A4 enzyme.

The medicine must be used with caution and is restricted for populations with hepatic impairment (liver dysfunction) or severe renal impairment (kidney dysfunction). Caution is also required for patients with pre-existing heart rhythm conditions or electrolyte imbalances, as these conditions necessitate careful eligibility assessment.

Age and Physiological Status

Funizol is approved for adults and pediatric patients over six months for established indications. However, safety and efficacy have not been established for many uses in children younger than six months. Use in older adults generally requires monitoring of renal function.

Use during pregnancy is not recommended for routine infections and is often contraindicated unless managing a severe, life-threatening fungal infection. The medicine is not routinely recommended during breastfeeding, though official guidance suggests a single dose is generally compatible with appropriate monitoring.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Funizol (Fluconazole) interacts with numerous medicines primarily by affecting their metabolism and clearance, which can significantly alter their concentrations in the body. This information is based solely on authoritative government regulatory documents.

Contraindicated Combinations

The co-administration of Funizol with certain drugs is strictly forbidden due to the risk of serious cardiac events, including QTc prolongation. These include: Astemizole, Cisapride, Pimozide, Quinidine, and Erythromycin. High-dose Funizol (400 mg/day) is also forbidden with Terfenadine.


Pharmacokinetic Interactions

Funizol is a documented inhibitor of the Cytochrome P450 enzymes CYP2C9 and CYP3A4, and a moderate inhibitor of CYP2C19. This effect increases the plasma concentrations of many co-administered medicines that are metabolized by these enzymes. Examples include certain Statins (e.g., Atorvastatin, Simvastatin), Immunosuppressants (e.g., Cyclosporine, Tacrolimus), and some Anticoagulants (e.g., Warfarin).

Conversely, some medicines can decrease Funizol's effectiveness. For instance, Rifampin is documented to decrease Funizol's overall systemic exposure ( AUC) by approximately 23%.


Food and Timing

Official labeling states that Funizol's absorption is unaffected by food. Therefore, there are no specific timing or separation requirements related to meals.

Mechanism of Action

How Funizol Works

Targeting the CYP51A1 Enzyme

Funizol, containing Fluconazole, acts as a specific inhibitor of the fungal enzyme Cytochrome P450 14alpha- lanosterol demethylase ( CYP51A1). By non-competitively binding to the enzyme’s active site, the drug immediately arrests a crucial step in the ergosterol biosynthesis pathway, which is necessary for the fungal cell's structural stability and reproduction. This molecular interference is the prerequisite for all subsequent physiological effects.


Structural Collapse and Growth Arrest (Fungistasis)

The blockade of CYP51A1 causes a severe depletion of ergosterol and leads to the toxic accumulation of abnormal precursor sterols within the fungal organism. This physiological disruption compromises the structural integrity and selective function of the fungal cell plasma membrane, preventing cell division and proliferation. The resulting fungistatic state functionally restricts the organism's proliferation, allowing host defense mechanisms to address the non-multiplying organism.

Dosage and Administration Information

How to use Funizol

Funizol (Fluconazole) usage follows specific administration protocols focusing on route, frequency, and duration patterns. The medicine is available for both Oral and Intravenous (IV) Infusion administration. Oral forms, including capsules, tablets, and suspension, can be taken with or without food.

Dosing and Frequency Principles

Most multi-dose regimens begin with a Loading Dose administered on the first day to rapidly achieve therapeutic levels. This is followed by a Maintenance Dose, typically administered once daily. For certain acute conditions, such as vaginal candidiasis, the application is often a single oral dose of 150 mg. The duration of treatment ranges from short-term (e.g., 7 to 14 days) to long-term suppressive therapy extending for several months, depending on the indication.

Administration Requirements

Feature Administration Principle Contextual Rule
Oral Suspension Must be shaken well prior to measurement. Use is independent of food intake.
IV Infusion Rate Must not exceed 200 mg per hour. Requires controlled, slow administration in a monitored setting.
Renal Adjustment Dose modification is necessary for patients with impaired kidney function (CrCl le 50 mL/min), often reducing the maintenance dose by 50% after the initial dose. The initial loading dose is generally not reduced.
Pediatric Dosing Based on body weight (mg/kg). Neonates require extended dosing intervals (e.g., every 72 hours) during the first two weeks of life.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Funizol

Evidence for Use in Treating Systemic Fungal Infections

Funizol was studied for serious, systemic fungal infections that have spread throughout the body, such as Invasive Candidiasis (including candidemia) and Cryptococcal Meningitis. Research examined different regimens using Randomized Controlled Trials (RCTs) and open-label studies. These trials were primarily used to monitor and measure outcomes like mycological clearance (the status of fungal cultures from sterile sites) and overall survival in the observed populations.

For Cryptococcal Meningitis, research was conducted during periods of increased symptom activity in immunocompromised adults, tracking outcomes related to the Cerebrospinal Fluid (CSF) sterilization rate and overall survival. Long-term observational research explored how symptoms evolved in the observed populations during the maintenance phase.

Evidence for Preventing Fungal Infections (Prophylaxis)

Studies were conducted during research exploring short-term symptom changes associated with periods of heightened symptom activity, particularly in high-risk patient groups where fungal infection prevention was the study focus. The research focused on patients receiving treatments, such as those undergoing bone marrow transplantation (BMT) or intensive chemotherapy, which lead to significant immune system changes. Randomized, Placebo-Controlled Trials were a major study design used to examine the use of Funizol before an infection occurred.

These studies monitored the incidence of systemic or superficial fungal infections and the time to onset of infection. Findings describe patterns where the incidence of fungal infections observed in the Funizol study arm was recorded as different from the incidence in the placebo study arm. Research in BMT recipients, for example, highlights changes measured across observed follow-up durations, which sometimes extended for years.

What Research Gaps and Uncertainties Remain

While the evidence base for Funizol is comprehensive across many approved uses, official and scientific reviews describe areas where research is ongoing and certainty remains low.

One key area is that comparative evidence is limited in large-scale RCTs against some of the newest generations of systemic antifungal medications. Long-term effects for many conditions are not fully established, as research exploring symptom evolution often does not extend beyond the acute treatment phase. Finally, continuous monitoring of fungal susceptibility remains an area of study, as research tracks the real-world development of azole-resistant strains.

Key Studies & References

  1. Antifungal Agents: General Overview (NCBI Bookshelf)
  2. Fluconazole Drug Information (NIH MedlinePlus)

Frequently Asked Questions (FAQ)

Common questions about Funizol (FAQ)


Q: What is the main difference between Funizol and other medicines used for the same thing?

A: Funizol is officially classified by regulatory agencies as a triazole antifungal agent, a group of medicines used to manage fungal infections. A notable feature described in the prescribing information is that Funizol is one of the available medicines in this class that is formulated for administration through both oral and intravenous (IV) routes. This dual availability is a key characteristic mentioned in official documents.


Q: Are there any common foods or drinks that should be avoided when taking Funizol?

A: According to the official product labeling, the absorption of Funizol is not affected by food, meaning it can be taken with or without a meal. However, regulatory documentation includes warnings and precautions regarding the co-administration of alcohol while taking this medicine. Any questions regarding specific consumption limitations should be directed to a healthcare provider.


Q: Is Funizol known to cause any long-term effects?

A: Official regulatory documents emphasize that continuous monitoring is required during long-term or chronic use of Funizol, particularly for potential severe hepatic injury (liver damage) and the development of azole resistance. The official safety information also notes risks associated with high-dose, long-term use during the first trimester of pregnancy.


Q: Are there specific symptoms that require immediate medical attention while on Funizol?

A: Official labeling states that immediate medical attention should be sought if certain symptoms of a serious adverse reaction are noticed. These include signs of a severe allergic reaction or skin condition, such as a spreading rash or blistering of the skin, yellowing of the skin or eyes (jaundice), or an irregular heartbeat.


Q: How are the risks and benefits of Funizol generally described in regulatory documents?

A: Regulatory documents describe Funizol as a medicine where the benefits of treating or preventing specific fungal infections are described as outweighing the potential risks. This assessment is made based on the premise that the medicine is used in accordance with the official prescribing conditions and safety warnings.


Q: Why is Funizol sometimes taken at night or in the morning?

A: Due to the medicine’s long elimination half-life, Funizol is typically administered just once a day, which provides flexibility in dosing time. Official product information notes that the exact timing of the dose (morning or night) is often chosen based on the need to manage potential side effects and patient convenience.


Q: Is Funizol supposed to make you feel drowsy?

A: According to regulatory drug safety documents, somnolence, which is the clinical term for drowsiness, is listed as an uncommon reported side effect of Funizol. The potential for side effects such as drowsiness requires consideration regarding activities like driving or operating machinery.


Q: Does Funizol stay in your system for a long time?

A: Official regulatory information, specifically the clinical pharmacology section, indicates that Funizol has a relatively long elimination half-life of approximately 30 hours. This prolonged presence in the body is the basis for its suitability for once-daily dosing regimens.


Q: If I miss a dose of Funizol, what should I generally do?

A: Official patient instructions for once-daily medicines generally advise that if a dose of Funizol is missed, the patient should take it as soon as they remember. However, if it is almost time for the next scheduled dose, regulatory guidance often outlines conditions under which skipping the missed dose and continuing the regular schedule may be appropriate.


Q: Can Funizol be taken by people who are generally healthy?

A: Funizol is a prescription medicine approved by regulatory agencies only for the treatment or prevention of specific fungal infections. It is not indicated for use by people who are otherwise generally healthy.


Q: What are the requirements for starting treatment with Funizol?

A: Official regulatory documents state that laboratory monitoring, particularly of liver function tests (LFTs), is typically required prior to starting treatment with Funizol. This monitoring is generally continued throughout the course of therapy to track changes in liver function.


Q: Does Funizol interact with herbal supplements?

A: Official regulatory documents warn that Funizol may affect the metabolism of certain co-administered substances. This caution applies to many medicines, and can also include certain herbal or nutritional supplements that act on the same liver enzyme pathways (known as Cytochrome P450 enzymes).


Q: Is Funizol a narcotic or a controlled substance?

A: Official government classification documents confirm that Funizol is not designated as a narcotic or a controlled substance. This classification means it does not fall under the specific federal regulations for substances with known potential for abuse.


Q: Can Funizol cause changes in mood or behavior?

A: Official regulatory documents list a range of psychiatric reactions as rare or uncommon reported side effects. These reactions include experiences such as anxiety, depression, and hallucinations.


Q: Are there any known interactions between Funizol and alcohol?

A: Official regulatory documentation includes specific warnings and precautions regarding the co-administration of alcohol while taking Funizol. Any questions regarding alcohol consumption should be directed to a healthcare provider.


Q: How is Funizol generally eliminated from the body?

A: According to regulatory documents, Funizol is primarily eliminated from the body through the kidneys via a process called renal clearance. The majority of the administered dose is excreted unchanged in the urine.


Q: Is Funizol a new medication, or has it been around for a while?

A: The active ingredient in Funizol was first approved for medicinal use by major regulatory authorities several decades ago. This makes it an established and widely recognized treatment option within the systemic antifungal class of medicines.


Q: Can Funizol be cut or crushed?

A: The precise administration instructions, including whether capsules or tablets should be swallowed whole or if they can be altered, are detailed in the official patient information. Following these instructions is necessary to ensure the medicine works as intended.


Q: Does Funizol affect the effectiveness of birth control pills?

A: Official regulatory documents state that Funizol may affect the metabolism of certain oral contraceptives. Because of this potential interaction, changes in the effectiveness of birth control pills can occur.


Q: What is the standard regulatory classification of Funizol (e.g., prescription only)?

A: Funizol is officially classified by regulatory authorities as a prescription-only medicine. This means that it cannot be legally obtained without authorization from a licensed healthcare provider.


Q: Does Funizol have potential for abuse or dependence?

A: Official regulatory documentation, including the drug abuse and dependence section, does not indicate that Funizol has a known potential for abuse or dependence. It is not classified as a controlled substance.


Q: What should be done if an overdose of Funizol is suspected?

A: Regulatory documents state that immediate emergency medical care or contact with a poison control center is necessary if an overdose of Funizol is suspected.


Q: Are there any official reports of dependence or withdrawal symptoms associated with Funizol?

A: Official regulatory documentation does not indicate a known risk of drug dependence or a specific withdrawal syndrome following proper discontinuation of Funizol. The medicine is not associated with the typical withdrawal effects seen with certain other drug classes.

How should Funizol be stored and disposed of?

The storage and disposal of Funizol (fluconazole) must adhere strictly to official regulatory requirements to ensure product stability and safety.

Storage Requirements

Formulation Required Storage Condition Stability/Handling Rule
Tablets/Capsules Store at Controlled Room Temperature (20 C to 25 C) in the original, tightly closed container.
Oral Suspension (Recon.) & IV Store between 5 C and 30 C (41 F and 86 F). Must be protected from freezing.

All dosage forms must be kept out of the sight and reach of children.

Stability and Disposal

The reconstituted oral suspension is stable for 14 days and must be discarded after this period. For unused or expired medicine, regulatory guidance advises mixing the product with an undesirable substance (such as coffee grounds or dirt) and placing it in a sealed container before disposal in household trash. Do not dispose of medicine via wastewater unless officially instructed.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Funizol found in:

A-Z Index: